We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Dap4.4
Dapagliflozin Research
Mostly mechanism / observationalLimited safety
6 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Dapagliflozin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2019–2022 with a typical study size of 6,263 participants.
Based on 6 studies · 1 meta-analysis · 4 RCTs · 66,793 total participants
Confidence
Moderate
By outcome
Cardiovascular & heart failure
Mostly mechanism / observational5 studies
Aging & healthspan (emerging)
Mostly mechanism / observational3 studies
Steady research
1 study in the last 5 years · Latest meta-analysis: 2019
20192022
1RCTn=4,744 · very large study2019
Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure and a reduced ejection fraction, regardless of diabetes status.
McMurray, Solomon, Inzucchi, Køber, Kosiborod, Martinez · The New England journal of medicine (2019)
DAPA-HF randomized trial in heart failure with reduced ejection fraction
Reduced the composite of worsening heart failure or cardiovascular death, and reduced all-cause mortality
Benefit was consistent in patients with and without type 2 diabetes
Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death in patients with heart failure and a mildly reduced or preserved ejection fraction (DELIVER).
Solomon, McMurray, Claggett, de Boer, DeMets, Hernandez · The New England journal of medicine (2022)
DELIVER randomized trial extending dapagliflozin to mildly reduced and preserved ejection fraction
Reduced worsening heart failure or cardiovascular death
Completes heart-failure benefit across the full ejection-fraction spectrum
Dapagliflozin did not result in a lower rate of major adverse cardiovascular events but did reduce the rate of cardiovascular death or hospitalization for heart failure (DECLARE-TIMI 58).
Wiviott, Raz, Bonaca, Mosenzon, Kato, Cahn · The New England journal of medicine (2019)
DECLARE-TIMI 58 large cardiovascular-outcomes RCT in type 2 diabetes
Did NOT reduce major adverse cardiovascular events (MACE) — the primary atherosclerotic endpoint was non-superior
Did reduce cardiovascular death or heart-failure hospitalization, establishing the heart-failure signal
SGLT2 inhibitors reduced the risk of heart-failure hospitalization and progression of renal disease, with more modest benefit on atherosclerotic major adverse cardiovascular events.